Niacinamide

Best-in-class: Niacinamide

The non-flushing form of vitamin B3 and a direct NAD+ precursor, with well-known skin-barrier and joint benefits.

How Niacinamide actually works

The non-flushing form of vitamin B3, and metabolically it is the direct precursor to NAD+ through the salvage pathway — bypassing the de novo route entirely. Unlike nicotinic acid it does not activate the GPR109A receptor in skin, which is what causes the flush, and it has no lipid-lowering effect at all. The two forms of B3 are genuinely different drugs above nutritional doses.

Where to get Niacinamide

The evidence for Niacinamide

Graded by what exists behind each claim.

✅ Clinically validated

• Topical/oral niacinamide improves skin barrier, tone and reduces some non-melanoma skin-cancer recurrence (RCT-supported).
• Raises NAD+ and supports energy metabolism; studied for joint comfort.

📊 Correlative data

• NAD+ and B3 status decline with age, tracking with skin and metabolic changes.

🧪 Theoretical / extrapolated benefits

• NAD+/longevity framing is popular; niacinamide raises NAD+ but hard longevity outcomes are unproven.

How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →

What Niacinamide actually does

Niacinamide and nicotinic acid are both called vitamin B3 and they are not interchangeable at a single receptor or a single enzyme. Niacinamide is nicotinic acid with the carboxylic acid replaced by a carboxamide. That one substitution removes the negative charge, and with it removes the entire pharmacology that made niacin a lipid drug and made it unbearable to take.

Where niacinamide enters NAD, in three steps with names. Nicotinamide phosphoribosyltransferase, NAMPT, condenses niacinamide with phosphoribosyl pyrophosphate to make nicotinamide mononucleotide. Nicotinamide mononucleotide adenylyltransferase — NMNAT1 in the nucleus, NMNAT2 in the cytosol and axon, NMNAT3 in mitochondria — adds AMP to make NAD. NAD synthetase is not needed on this route. NAMPT is the rate-limiting step of the salvage pathway and the reason niacinamide is an efficient NAD precursor: it re-enters the loop exactly where the cell's own recycling happens.

Nicotinic acid enters somewhere else entirely. Nicotinate phosphoribosyltransferase, NAPRT, starts the Preiss-Handler route, which needs an extra ATP-dependent step through NAD synthetase. Same destination, different door, different tissue distribution — NAPRT expression is high in liver, gut and kidney and low elsewhere, which is one reason the two forms do not behave identically at the tissue level.

The flush has a receptor and niacinamide does not bind it. Nicotinic acid is an agonist at the G-protein-coupled receptor HCA2, better known by its old names GPR109A, HM74A and PUMA-G. In receptor-knockout animals the flush disappears, which is as clean a demonstration of mechanism as this literature contains Benyo 2005. The receptor sits on epidermal Langerhans cells and keratinocytes; agonism drives cyclooxygenase-dependent prostaglandin D2 and E2 release, those prostanoids dilate dermal vessels, and the result is the burning red face at twenty minutes. The same receptor on the adipocyte suppresses lipolysis, which is the root of nicotinic acid's effect on free fatty acid flux and therefore on hepatic triglyceride and lipoprotein output. Niacinamide has essentially no agonist activity there. So niacinamide does not flush and niacinamide does not move lipids, and those two facts are the same fact.

What NAD is spent on, which is where the skin story comes from. Three families consume NAD rather than cycle it: poly(ADP-ribose) polymerases, chiefly PARP1, which are activated within seconds of DNA strand breaks; the sirtuin deacylases; and CD38. Ultraviolet light does two things to a keratinocyte at once — it breaks DNA, which switches on PARP1, and it inhibits glycolysis, which is where the cell was going to get the ATP for repair. The result is a cell that is energy-starved precisely when it needs to excise a pyrimidine dimer. Supplying niacinamide restores the NAD pool and the glycolytic ATP, and enhanced repair plus reduced ultraviolet immunosuppression is the proposed chemoprevention mechanism.

The barrier effect is a separate lipid mechanism. In cultured human keratinocytes niacinamide increased ceramide synthesis along with free fatty acids and cholesterol, and raised serine palmitoyltransferase activity — the committed step of sphingolipid synthesis Tanno 2000. Ceramides, cholesterol and free fatty acids in roughly equimolar proportion are what the stratum corneum lipid lamellae are made of, so this is a claim about building material rather than about signaling.

And one inconvenient enzyme. Nicotinamide N-methyltransferase, NNMT, disposes of excess niacinamide by methylating it to 1-methylnicotinamide, and the methyl group comes from S-adenosylmethionine Hong 2015. Every gram of niacinamide you swallow is therefore a claim on the same methyl budget that folate, B12 and betaine exist to defend — which is a real and rarely-stated link between this page and this site's methylation page.

Cell, rodent, human — and where it stops

In cells. Cultured human keratinocytes, niacinamide in the millimolar range, days: ceramide and stratum corneum lipid synthesis rise, with serine palmitoyltransferase activity up Tanno 2000. Millimolar is a concentration a topical formulation can reach in the epidermis and an oral dose cannot reach in plasma, which is the reason the topical and oral literatures are not the same literature.

In animals. The flush mechanism was settled in receptor-knockout mice, where deleting HCA2/GPR109A abolished nicotinic acid-induced vasodilation Benyo 2005. That is an animal result which transfers cleanly, because the human observation it explains — take nicotinic acid, go red; take niacinamide, do not — is one anybody can reproduce in twenty minutes.

In people, topical, for acne. Four per cent nicotinamide gel against 1% clindamycin gel, eight weeks, in patients with moderate inflammatory acne: comparable improvement in lesion counts and severity Shalita 1995. The interesting part of that trial is not that it worked but that it matched an antibiotic without being one, which is an argument about resistance rather than about efficacy.

In people, oral, for the barrier. A randomized controlled trial of oral nicotinamide reduced transepidermal water loss Chen 2016. Transepidermal water loss is the standard instrumented read-out of barrier integrity and it is measured with a probe, not by how the skin feels.

In people, oral, for skin cancer — and this is the trial the product is really sold on. Three hundred and eighty-six participants with a history of at least two keratinocyte cancers in the previous five years, 500 mg of nicotinamide twice daily for twelve months against placebo: about a 23% lower rate of new non-melanoma skin cancers, with actinic keratosis counts also reduced, and the benefit did not persist after the tablets stopped Chen 2015. A relative reduction of that size in a population with that much disease is a real clinical result.

And then the trial that most pages selling this molecule do not mention. The same 500 mg twice-daily regimen was tested in solid-organ transplant recipients — a group whose keratinocyte cancer risk is far higher and whose need is therefore far greater — and it did not reduce skin cancers Allen 2023. Two randomized trials of the same drug at the same dose, one positive and one null, in populations that differ mainly in immunosuppression.

The specific obstacle, and it is a population obstacle. Everything positive here was measured in people with a disease: diagnosed acne, damaged barrier, a history of multiple skin cancers. The 23% is a relative reduction on a large baseline rate; a person who has never had a keratinocyte cancer has an annual risk small enough that 23% of it is not something they or their dermatologist could ever observe. And the transplant null Allen 2023 suggests the mechanism needs a functioning immune system to work through, which would mean the benefit is not simply proportional to risk. Buying this for general skin health is buying a trial result that was measured in a clinic.

Niacinamide — which form, and does it matter

Four molecules are sold as vitamin B3 and only two of them do anything the label claims. Nicotinic acid, or niacin, is the HCA2 agonist: it flushes, it lowers triglycerides and raises HDL, and it is the only form with a lipid indication Benyo 2005. Niacinamide, or nicotinamide, is the salvage-pathway precursor: no flush, no lipid effect, and the form used in every trial cited on this page Chen 2015Chen 2016. Inositol hexanicotinate, sold as no-flush niacin, is six nicotinic acid molecules esterified to an inositol; it is hydrolyzed poorly and slowly in humans, which is exactly why it does not flush, and it is also why it does not reliably move lipids — the absence of the flush is the absence of the drug. Nicotinamide riboside and nicotinamide mononucleotide enter one step further along and are the subject of separate pages here; chronic nicotinamide riboside at 1,000 mg a day raises whole-blood NAD in middle-aged and older adults and is well tolerated Martens 2018, which is the comparison this page's molecule has never been made to face.

Match the dose to the claim you are buying. The skin-cancer trials used 500 mg twice daily, one gram a day Chen 2015Allen 2023. This site's card gives 500 mg once or twice daily, so its upper end is the trial dose and its lower end is half of it. For the barrier claim the acne evidence is topical at 4% Shalita 1995 and is not delivered by a capsule.

The form question the NAD marketing does not want asked. Niacinamide is the cheapest NAD precursor by an order of magnitude and it enters the salvage pathway at the same NAMPT step the expensive ones are marketed as bypassing. Nobody has run niacinamide against nicotinamide riboside at equimolar dose with whole-blood NAD as the shared endpoint, which means the premium on the newer molecules is currently a mechanistic argument rather than a measured one Martens 2018.

What would have to be true, and how you would know it was not

1. Your lipid panel will not move, and that is the test that separates this from niacin. Full lipid panel before and after twelve weeks at a gram a day. Predict no change in triglycerides, no change in HDL and no change in ApoB, because the receptor that produces those effects is not one niacinamide binds Benyo 2005. Anybody who bought this expecting the cholesterol benefit of niacin has bought the wrong molecule, and this is the blood test that says so.

2. No flush, ever, at any dose you will take. If a B3 product makes you go red at twenty minutes, it contains nicotinic acid — whatever the front of the bottle says. That is a one-dose identity test with a receptor behind it Benyo 2005.

3. Actinic keratosis count, at six months, and only if you have them. Have a dermatologist count and map them at baseline and at six months on 500 mg twice daily. In a person with a history of multiple keratinocyte cancers, predict fewer new lesions Chen 2015. In a person who has never had one, predict nothing measurable, because 23% of a very small annual risk is not an observable quantity in one human being.

4. The prediction that cuts against the product: stopping reverses it. The chemoprevention benefit did not persist once tablets stopped Chen 2015, which means this is a maintenance drug rather than a repair. If you were told niacinamide fixes photodamage, the trial says otherwise: it suppresses new lesion formation while you take it.

5. Labeled extrapolation, and it is the interesting one. Fasting homocysteine before and after eight weeks at a gram a day. Nicotinamide N-methyltransferase disposes of surplus niacinamide by spending a methyl group from S-adenosylmethionine Hong 2015, and spent methyl groups leave homocysteine behind. Predict a small rise — on the order of one micromole per liter — in someone with marginal folate or B12 status, and no change in someone replete. Nobody has run this. It is one blood test and it would tell you whether the gram-a-day habit needs a methyl donor alongside it.

What will fool you: winter. Barrier measurements and skin comfort track ambient humidity harder than they track anything you swallow, so a product started in October looks miraculous by May Chen 2016.

What nobody has tested yet

Nobody knows why the transplant trial failed. Two randomized trials, same molecule, same 500 mg twice daily, opposite results Chen 2015Allen 2023. The obvious hypothesis is that the mechanism needs an intact immune surveillance the immunosuppressed do not have — that reduced ultraviolet immunosuppression, not enhanced DNA repair, is where the benefit came from. Nobody has tested that directly, and a trial that measured contact hypersensitivity responses alongside lesion counts in both populations would settle it.

Nobody has measured NAD in a person taking niacinamide for skin. Not one of the dermatology trials reports whole-blood or skin NAD. The mechanism on this page is an NAD mechanism, the assay exists and has been used for the newer precursors Martens 2018, and the connection between dose, NAD and lesion count has never been drawn in the same study.

Nobody has run the average-risk trial, and there is a reason. Establishing a 23% reduction in a population whose baseline rate is a fraction of a percent per year needs tens of thousands of people for a decade. That trial will probably never exist, which means the honest position for a person with sun-damaged skin and no cancer history is that they are extrapolating, cheaply and fairly safely, from a population sicker than themselves.

And nobody has measured the methyl cost. 1-methylnicotinamide excretion, plasma S-adenosylmethionine, S-adenosylhomocysteine and homocysteine, before and after twelve weeks at a gram a day Hong 2015. Four assays, thirty people, and it would answer whether chronic high-dose niacinamide quietly consumes the methyl supply that the rest of the supplement shelf is sold to protect.

Niacinamide — its own safety story, not its category's

The 35 mg upper limit is real and it is not about this molecule's toxicity. The tolerable upper intake level for niacin in adults is 35 mg a day, and the endpoint that set it is flushing from nicotinic acid — a cosmetic, self-limiting effect at a receptor niacinamide does not bind Benyo 2005. Applying that number to niacinamide is a category error that appears on a great many labels. The dose that matters for niacinamide is the hepatic one: the traditional threshold of concern is around 3 g a day, and the trials here ran at a third of that for a year with liver monitoring and no signal Chen 2015.

So the number to watch is a transaminase, not a flush. If you are taking a gram a day for more than a few months, an ALT and an AST at three months and then annually is the whole safety program, and it costs almost nothing. The risk is concentrated in people already carrying liver disease, drinking heavily, or taking other hepatically-handled agents.

Glucose, and this is genuinely unsettled. High-dose niacinamide has been reported to reduce insulin sensitivity, and the mechanistic case runs through the same NAD and methyl-consumption biology as the rest of this page Hong 2015. It is not established at the doses on this card, but a person with prediabetes taking a gram a day has a cheap way to check: fasting glucose and HbA1c at baseline and six months.

What it does not do, listed because absence is a safety property. It does not flush, so it will not warn you it has landed. It does not lower cholesterol, so it should not be substituted for a lipid therapy Benyo 2005. It does not have the hepatotoxicity profile of sustained-release nicotinic acid, which is a different molecule in a different formulation and is where most of the serious B3 liver injury in the literature comes from.

Stacking, which is the practical risk. Niacinamide appears inside multivitamins at 100 to 150 mg — the Thorne panels in this cohort declare 130 mg per daily dose Office of Dietary SupplementsOffice of Dietary Supplements — and inside NAD products as a degradation product of the newer precursors. A gram of standalone niacinamide on top of a high-potency multi is the realistic total, and it is worth adding up before deciding that the liver test is unnecessary.

Sources read for this page

• Chen AC, et al. A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention.. New England Journal of Medicine 2015 · PMID 26488693
• Allen NC, et al. Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients.. New England Journal of Medicine 2023 · PMID 36856616
• Benyo Z, et al. GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing. Journal of Clinical Investigation 2005 · PMID 16322797
• Chen AC, et al. Oral nicotinamide reduces transepidermal water loss: a randomized controlled trial.. British Journal of Dermatology 2016 · PMID 27062605
• Shalita AR, et al. Topical nicotinamide compared with clindamycin gel in the treatment of inflammatory acne vulgaris.. International Journal of Dermatology 1995 · PMID 7657446
• Tanno O, et al. Nicotinamide increases biosynthesis of ceramides as well as other stratum corneum lipids to improve the epidermal permeability barrier.. British Journal of Dermatology 2000 · PMID 10971324
• Martens CR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD(+) in healthy middle-aged and older adults. Nature Communications, 2018 · PMID 29599478
• Hong S, Moreno-Navarrete JM, Wei X, Kikukawa Y, Tzameli I, Prasad D, Lee Y, Asara JM, Fernández-Real JM, Maratos-Flier E, Pissios P. Nicotinamide N-methyltransferase regulates hepatic nutrient metabolism through Sirt1 protein stabilization. Nature Medicine 2015;21(8):887–894 · PMID 26168293

How you would know if it worked

Niacinamide — safety & side effects

Bloodwork to run alongside Niacinamide

Baseline first, then again at 8–12 weeks.

The Full Micronutrient Screen panel covers these in one order — 11 markers, $363.60 with the discount applied.

Check results you already have → · All 103 markers A–Z

Niacinamide — frequently asked questions

Niacinamide inside a finished plan

One arm of 1 Protocol Blueprint, free to read in full.

What Niacinamide is used for

Niacinamide appears under 2 goals in the goal router.

Related Vitamins supplements

← Browse the full Supplement Vault

↑ Back to on this page